Eric Halioua's Biography

Eric Halioua, Chief Executive Officer/Co-founder, Promethera Biosciences

Eric Halioua is the CEO of the Belgian Biotechnology company Promethera Biosciences. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using stem cell from healthy human livers. He is as well Board members of the European Biopharmaceutical Enterprises (EBE) and of the Belgian Walloon region Biocluster (BioWin).
Eric is co-founder of two biotechnology companies called Myosix and Murigenetics. Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been sold to Genzyme mid-2002. Murigenetics is a Biotechnology company developing therapies for genetic disorders.
Eric was also a Board Member of a French public biotechnology company called Vivalis, which specializes in the production of avian stem cells lines for the production of vaccines and recombinant proteins.
Eric was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during 11 years. He has led work in the areas of strategy, M&A and technology & innovation management for biotechnology and pharmaceutical companies. Eric also worked as a strategic marketing manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Zeneca in UK.
Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.